OTCMKTS:RSPI Cortex Pharmaceuticals (RSPI) Stock Price, News & Analysis $0.0018 0.00 (0.00%) As of 05/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Cortex Pharmaceuticals Stock (OTCMKTS:RSPI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cortex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0018▼$0.001850-Day Range N/A52-Week Range$0.0001▼$0.0027VolumeN/AAverage VolumeN/AMarket Capitalization$1.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cortex Pharmaceuticals, Inc. (OTCMKTS: RSPI) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapeutics for the treatment of central nervous system disorders. The company’s proprietary platform centers on positive allosteric modulators of the AMPA receptor, commonly known as ampakines, which are designed to enhance synaptic transmission and support neuronal function in a variety of neurological conditions. The company’s lead product candidates include CX717, CX1739 and CX1942, each of which is being evaluated for distinct indications such as opioid-induced respiratory depression, attention-deficit/hyperactivity disorder (ADHD) and cognitive impairment associated with aging or disease. Cortex has advanced these compounds through preclinical and early-stage clinical studies and has collaborated with pharmaceutical partners to explore broader therapeutic applications and formulation strategies. Founded in 1996 and headquartered in Irvine, California, Cortex Pharmaceuticals operates a research facility staffed by scientists with deep expertise in neuropharmacology and drug development. The management team brings together years of experience in advancing investigational therapies from discovery through clinical proof-of-concept, with the goal of addressing unmet medical needs in neurology. Cortex continues to refine its pipeline through strategic collaborations and internally driven research initiatives, seeking to translate its ampakine technology into safe and effective treatments that improve patient outcomes across multiple neurological indications.AI Generated. May Contain Errors. Read More Receive RSPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RSPI Stock News HeadlinesRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested PartiesNovember 20, 2025 | globenewswire.comRespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License AgreementNovember 19, 2025 | globenewswire.comThe SpaceX filing is public. The window is closing.SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.May 26 at 1:00 AM | Behind the Markets (Ad)RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common StockNovember 18, 2025 | markets.businessinsider.comRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, ...February 10, 2025 | gurufocus.comRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 29, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc (RSPI)May 23, 2024 | investing.comRespireRx Pharmaceuticals Inc RSPIMay 1, 2024 | morningstar.comMSee More Headlines RSPI Stock Analysis - Frequently Asked Questions How have RSPI shares performed this year? Cortex Pharmaceuticals' stock was trading at $0.0018 at the beginning of the year. Since then, RSPI stock has increased by 0.0% and is now trading at $0.0018. How were Cortex Pharmaceuticals' earnings last quarter? Cortex Pharmaceuticals Inc. (OTCMKTS:RSPI) issued its earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Cortex Pharmaceuticals? Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cortex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cortex Pharmaceuticals investors own include American Bio Medica (ABMC), Galaxy Next Generation (GAXY), Asia Broadband (AABB), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET) and AMC Entertainment (AMC). Company Calendar Last Earnings8/19/2020Today5/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:RSPI CIK849636 Webwww.respirerx.com Phone(201) 444-4947Fax949-727-3657Employees2Year Founded1988Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares949,460,000Free Float474,447,000Market Cap$1.71 million OptionableNot Optionable Beta0.59 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:RSPI) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTim Plaehn's income ETF research is available at 82% off - but only until midnight tonight. This Memorial Day ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortex Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
